Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX26 plus Serplulimab and Chemotherapy in Advanced NSCLC
NCT05787613Phase 2Active, not recruiting
- Sponsor
- Henlius
- Start
- Jul 2023
- Primary completion
- Feb 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of hlx26 in non-small cell lung cancer (NSCLC), sponsored by Henlius. Started Jul 2023; status: active, not recruiting.
02
Drugs
hlx26
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05787613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05787613.